The NR G Oncology report on the combination of OBP-301 with chemoradiation in esophageal cancer was published in an overseas journal. Safety showed no DLTs, clinically complete responses achieved in all 13 evaluable patients, 1-year survival rate 60%, discussions with domestic experts on future development plans. Impact on fiscal period is unknown.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"OncoRIS Biopharma, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4588-20260630-01.pdf","jir_short_summary":" The NR G Oncology report on the combination of OBP-301 with chemoradiation in esophageal cancer was published in an overseas journal. Safety showed no DLTs, clinically complete responses achieved in all 13 evaluable patients, 1-year survival rate 60%, discussions with domestic experts on future development plans. Impact on fiscal period is unknown.","jir_summary":"### News overview\nOncoRIS Biopharma announced that the results of the NRG-GI007 trial of OBP-301 in combination with chemoradiation for patients with esophageal cancer were published in an international journal. The trial was conducted from June 2020 to July 2024, enrolling 15 patients and administering OBP-301 per protocol. No DLTs were observed, safety was assessed for all patients, and treatment-related severe adverse events were mainly neutropenia and lymphopenia. Clinically complete response (clinical CR) was 100% among the 13 evaluable patients and 87% among all 15 patients. One-year survival rate was 60%, and progression-free survival was 53%.\n\n### Future plans and impact\nBased on these results, the company plans to decide on future development directions for this treatment regimen in the esophageal cancer field in consultation with domestic specialists. TerMeilysin (OBP-301) is already approved in Japan as a regenerative medicine product for radiation-combined treatment of esophageal cancer. It is stated that there will be no impact on the financial results for the fiscal year ending December 2026.","jir_financial_highlights":"Financial impact: Unknown (Unknown)","jir_category":"","jir_hashtags":"#OncoRISBiopharma, #OBP301, #NRGOncology","jir_key_figures":"Clinical trial: NRG-GI007\nPatients evaluable for efficacy: 13\nClinically complete response: 100% (of 13)\nClinically complete response across all patients: 87%\nOne-year survival rate: 60%\nProgression-free survival: 53%","jir_meta_title":"OncoRIS Biopharma: OBP-301 with Radiation Therapy: Clinical Trial Results Published | June 2026","jir_meta_description":"Publication of safety and efficacy indicators for OBP-301 in combination with chemoradiation for esophageal cancer (NRG-GI007). Future development plans to be discussed with domestic specialists. No impact on earnings expected.","jir_og_title":"OncoRIS Biopharma: OBP-301 Combined Therapy Clinical Results Published","jir_og_description":"Publication of the esophageal cancer trial of OBP-301 in combination with radiation. Safety: no DLTs; clinical CR: 100% (13 patients); 1-year survival rate: 60%. Future plans to be discussed with domestic experts.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-73255","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n